JP2023516615A - ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ - Google Patents

ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ Download PDF

Info

Publication number
JP2023516615A
JP2023516615A JP2022551667A JP2022551667A JP2023516615A JP 2023516615 A JP2023516615 A JP 2023516615A JP 2022551667 A JP2022551667 A JP 2022551667A JP 2022551667 A JP2022551667 A JP 2022551667A JP 2023516615 A JP2023516615 A JP 2023516615A
Authority
JP
Japan
Prior art keywords
adm
therapy
dpp3
shock
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551667A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516615A5 (https=
JPWO2021170838A5 (https=
Inventor
ベルクマン アンドレアス
Original Assignee
４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2023516615A publication Critical patent/JP2023516615A/ja
Publication of JP2023516615A5 publication Critical patent/JP2023516615A5/ja
Publication of JPWO2021170838A5 publication Critical patent/JPWO2021170838A5/ja
Priority to JP2025179567A priority Critical patent/JP2026035582A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2022551667A 2020-02-27 2021-02-26 ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３ Pending JP2023516615A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025179567A JP2026035582A (ja) 2020-02-27 2025-10-24 ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20159848 2020-02-27
EP20159848.9 2020-02-27
PCT/EP2021/054911 WO2021170838A1 (en) 2020-02-27 2021-02-26 Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025179567A Division JP2026035582A (ja) 2020-02-27 2025-10-24 ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３

Publications (3)

Publication Number Publication Date
JP2023516615A true JP2023516615A (ja) 2023-04-20
JP2023516615A5 JP2023516615A5 (https=) 2024-02-29
JPWO2021170838A5 JPWO2021170838A5 (https=) 2024-02-29

Family

ID=69742802

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022551667A Pending JP2023516615A (ja) 2020-02-27 2021-02-26 ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３
JP2025179567A Pending JP2026035582A (ja) 2020-02-27 2025-10-24 ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025179567A Pending JP2026035582A (ja) 2020-02-27 2025-10-24 ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３

Country Status (9)

Country Link
US (1) US20230193348A1 (https=)
EP (1) EP4111204A1 (https=)
JP (2) JP2023516615A (https=)
CN (1) CN115244401A (https=)
AU (1) AU2021228207A1 (https=)
BR (1) BR112022015215A2 (https=)
CA (1) CA3172349A1 (https=)
MX (1) MX2022010672A (https=)
WO (1) WO2021170838A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010564A (es) * 2020-02-27 2022-11-30 Adrenomed Ag Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque.
KR20250042158A (ko) 2022-07-29 2025-03-26 아드레노메드 아게 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
CN119630969A (zh) 2022-07-29 2025-03-14 4Teen4制药有限公司 预测患有败血症性休克的患者中的dpp3增加
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019077082A1 (en) * 2017-10-18 2019-04-25 Adrenomed Ag SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM)
WO2019081595A2 (en) * 2017-10-25 2019-05-02 Sphingotec Therapeutics Gmbh DPP3 BINDER DIRECTED TO AND BINDING SPECIFIC DPP3 EPITOPES AND USE THEREOF IN THE PREVENTION OR TREATMENT OF OXIDATIVE STRESS ASSOCIATED DISEASES / CONDITIONS
JP2019520550A (ja) * 2016-04-21 2019-07-18 スフィンゴテック セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ３の定量方法および治療方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
EP1620734A1 (en) 2003-04-25 2006-02-01 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
PL2594588T3 (pl) 2011-11-16 2014-11-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
DK2780371T3 (en) 2011-11-16 2019-02-25 Adrenomed Ag ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE
EP4086283A1 (en) 2011-11-16 2022-11-09 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019520550A (ja) * 2016-04-21 2019-07-18 スフィンゴテック セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ３の定量方法および治療方法
WO2019077082A1 (en) * 2017-10-18 2019-04-25 Adrenomed Ag SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM)
WO2019081595A2 (en) * 2017-10-25 2019-05-02 Sphingotec Therapeutics Gmbh DPP3 BINDER DIRECTED TO AND BINDING SPECIFIC DPP3 EPITOPES AND USE THEREOF IN THE PREVENTION OR TREATMENT OF OXIDATIVE STRESS ASSOCIATED DISEASES / CONDITIONS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. DENIAU ET AL.: "Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibit", EUR J HEART FAIL, vol. 22, JPN6024052981, 31 August 2019 (2019-08-31), pages 290 - 299, ISSN: 0005497695 *
GEVEN C. ET AL: "A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase", BMJ OPEN, vol. 9, JPN6024052983, 6 February 2019 (2019-02-06), pages 024475, ISSN: 0005497693 *
REHFELD LINDA ET AL.: "Novel Methods for the Quantification of Dipeptidyl Peptidase 3 (DPP3) Concentration and Activity in", THE JOURNAL OF APPLIED LABORATORY MEDICINE, vol. Vol.3, Iss.6, JPN7024005550, 1 May 2019 (2019-05-01), pages 943 - 953, ISSN: 0005497692 *
TAKAGI K. ET AL.: "Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results fro", EUR J HEART FAIL, vol. 22, JPN6024052982, 31 August 2019 (2019-08-31), pages 279 - 286, ISSN: 0005497694 *

Also Published As

Publication number Publication date
US20230193348A1 (en) 2023-06-22
CN115244401A (zh) 2022-10-25
MX2022010672A (es) 2022-09-23
JP2026035582A (ja) 2026-03-04
AU2021228207A1 (en) 2022-10-20
WO2021170838A1 (en) 2021-09-02
BR112022015215A2 (pt) 2022-10-11
EP4111204A1 (en) 2023-01-04
CA3172349A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
AU2020338818B2 (en) Therapy guidance and/or therapy monitoring for treatment of shock
JP2026035582A (ja) ショックを患っている患者におけるｎｔ－ａｄｍ抗体治療法ガイダンス、モニタリング、及び層別化のためのｄｐｐ３
US20230104578A1 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
JP2023518731A (ja) コロナウイルスに感染した患者におけるｄｐｐ３
JP2025063078A (ja) アンジオテンシン受容体アゴニストおよび／またはその前駆体による治療のための治療ガイドおよび／または治療モニタリング
US20260028423A1 (en) Prediction of an increase of dpp3 in a patient with septic shock
JP2025541138A (ja) 重篤な患者における肺機能の改善のためのｄｐｐ３阻害剤
RU2838370C1 (ru) Dpp3 для осуществления, мониторинга и стратификации терапии nt-adm антителами у пациентов с шоком
RU2855130C2 (ru) Антитело против адреномедуллина (adm), или фрагмент антитела против adm, или анти-adm не-ig каркас для применения в терапии или профилактике шока
RU2854796C1 (ru) Связующее вещество против адреномедуллина (adm) для применения в терапии пациентов в состоянии шока
JP2025525059A (ja) ショックの治療又は予防に使用するための抗アドレノメデュリン（ＡＤＭ）抗体若しくは抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
CA3207969A1 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock and prediction of an increase of dpp3 in a critically ill patient
EP4687942A1 (en) Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
JP2026513177A (ja) 血圧低下を有する重症患者における心筋保護及び心筋傷害の予防のためのｄｐｐ３阻害剤
JP2023515985A (ja) ショック状態の患者の治療において使用するための抗アドレノメデュリン（ａｄｍ）結合剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250407

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251028